What is Gain Therapeutics, Inc.'s (GANX) StockRank?

MoatMap's StockRank for Gain Therapeutics, Inc. (GANX) is 3/100, with a Strong Sell signal. This is a composite score combining Quality (26), Value (34), and Momentum (18) factor ranks across MoatMap's 20,000+ stock universe.

Does Gain Therapeutics, Inc. have an economic moat?

Gain Therapeutics, Inc. (GANX) has a Quality factor score of 26/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Gain Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Gain Therapeutics, Inc. (GANX) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Gain Therapeutics, Inc. in?

Gain Therapeutics, Inc. (GANX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

GANX

STRONG SELLREMOVE

Gain Therapeutics, Inc. · Healthcare · United States · $86M · Avg Vol: $1M/d

StockRank

P/E (TTM)

—

ROE

-214.7%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Gain Therapeutics is a pre-revenue biotechnology company focused on computationally-designed therapies. It lacks the established commercial platform, high ROIC, and predictable cash flows required by our quality-focused investment philosophy.

COMPANY DESCRIPTION

Gain Therapeutics, Inc. is a clinical-stage biotechnology company utilizing its proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to discover novel allosteric regulators. This computational platform serves as a key competitive moat, identifying drug candidates for neurodegenerative diseases and lysosomal storage disorders. The company operates as a niche innovator at the intersection of artificial intelligence and drug discovery.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	140,108	55,180	0	0	-60.6%
EPS	-1.48	-1.71	-0.89	-0.61	—
Shares	12M	16M	27M	42M	+254.1%
Debt	1M	1M	653,015	732,067	-16.9%
Equity	19M	13M	7M	19M	-0.6%
Op CF	-15M	-19M	-19M	-18M	—
Inv CF	-15M	10M	5M	0	—
Fin CF	-78,774	13M	13M	28M	—

PRICE (1M)-6.8%

SMA 50SMA 200

$1.78

RSI (14)

33.3

52W High

$4.34

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-96.1%5.3

ROE

-214.7%3.3

GP/Assets

-44.1%1.5

Op. Margin

0.0%40.4

FCF/Assets

-48.7%4.8

Piotroski

—28.7

Int. Cover

—N/A

D/E Ratio

0.05x74.6

Current Ratio

4.69x68.6

Value

P/E (TTM)

—N/A

EV/EBITDA

-2.8x69.2

P/FCF

—N/A

P/B

5.1x23.6

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

41%13.6

RS 6M

-64%16.3

SMA 50/200

0.84x19.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-3%19.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$86M

P/E (Forward)

-2.8x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GANX are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
GANX	Gain Therapeutics, Inc.(you)	$86M	3	STRONG SELL
SGMO	Sangamo Therapeutics, Inc.	$87M	3	STRONG SELL
ATYR	aTyr Pharma, Inc.	$82M	3	STRONG SELL
ANVS	Annovis Bio, Inc.	$81M	1	STRONG SELL
2257.HK	Sirnaomics Ltd.	$82M	7	STRONG SELL
KALA	KALA BIO, Inc.	$104M	2	STRONG SELL
ANIX	Anixa Biosciences, Inc.	$91M	7	STRONG SELL
ALDX	Aldeyra Therapeutics, Inc.	$106M	5	STRONG SELL
AARD	Aardvark Therapeutics, Inc.	$92M	7	STRONG SELL
ESLA	Estrella Immunopharma, Inc.	$62M	3	STRONG SELL

Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%

Gain Therapeutics, Inc. (GANX) — Stock Score Summary

Gain Therapeutics, Inc. (GANX) has a MoatMap StockRank of 3/100 based on Quality (26/100), Value (34/100), and Momentum (18/100) factor scores. The current signal is STRONG SELL. Gain Therapeutics is a pre-revenue biotechnology company focused on computationally-designed therapies. It lacks the established commercial platform, high ROIC, and predictable cash flows required by our quality-focused investment philosophy.

Key Financial Metrics

Price	$1.78
Market Cap	$86M
P/E (Forward)	-2.80
Price/Book	5.09
Return on Equity	-214.7%
Return on Invested Capital	-96.1%
Debt/Equity	4.80
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-11M

Gain Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Gain Therapeutics, Inc.’s (GANX) StockRank?: MoatMap’s StockRank for Gain Therapeutics, Inc. (GANX) is 3/100, with a Strong Sell signal. It is a composite of Quality (26), Value (34), and Momentum (18) factor ranks across MoatMap’s 20,000+ stock universe.
Does Gain Therapeutics, Inc. have an economic moat?: Gain Therapeutics, Inc. (GANX) has a Quality factor score of 26/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Gain Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Gain Therapeutics, Inc. (GANX) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Gain Therapeutics, Inc. in?: Gain Therapeutics, Inc. (GANX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).